Here are what the editors at HealthDay consider to be the most important developments in Urology for September 2020. This roundup includes the latest research news from journal articles, as well as the FDA approvals and regulatory changes that are the most likely to affect clinical practice.
Hospital Admissions Not Related to COVID-19 Fell in Early 2020
WEDNESDAY, Sept. 30, 2020 (HealthDay News) — Non-COVID-19 hospital admissions decreased considerably with the onset of COVID-19, with declines generally similar across patient demographic subgroups from February to April 2020, according to a report published online Sept. 24 in Health Affairs.
Cancer Mortality Higher for U.S. Counties With Persistent Poverty
WEDNESDAY, Sept. 30, 2020 (HealthDay News) — U.S. counties with persistent poverty (â‰¥20 percent of residents in poverty since 1980) have higher rates of cancer mortality, according to a study published online Sept. 30 in Cancer Epidemiology, Biomarkers & Prevention.
Company Pays $60 Million to Settle Pelvic Mesh Case
MONDAY, Sept. 28, 2020 (HealthDay News) — A company has agreed to pay $60 million to settle charges by U.S. state attorneys general that it failed to adequately inform women of dangerous side effects associated with permanent pelvic mesh devices.
Private Health Plans Pay Hospitals 247 Percent of Medicare
MONDAY, Sept. 28, 2020 (HealthDay News) — During 2018, prices paid to hospitals by privately insured patients averaged 247 percent of what Medicare would have paid, according to a study from the RAND Corporation.
Ultrasound Ablation Offers Option for Some With Prostate Cancer
WEDNESDAY, Sept. 16, 2020 (HealthDay News) — For men with localized prostate cancer, hemigland high-intensity focused ultrasound (HIFU) ablation is associated with 73 percent two-year survival free from treatment failure and 91 percent survival free from radical treatment, according to a study published in the October issue of The Journal of Urology.
PPI Use Is Negative Prognostic Marker in Urothelial Cancer
WEDNESDAY, Sept. 16, 2020 (HealthDay News) — For patients with advanced urothelial cancer treated with atezolizumab, proton pump inhibitor (PPI) use is a negative prognostic marker, according to a study published online Sept. 15 in Clinical Cancer Research.
Darolutamide Boosts Survival in Nonmetastatic Prostate Cancer
TUESDAY, Sept. 15, 2020 (HealthDay News) — For men with nonmetastatic, castration-resistant prostate cancer, the risk for death is significantly lower for those receiving darolutamide versus placebo, according to a study published in the Sept. 10 issue of the New England Journal of Medicine.